OOS Failures Addressed
This article was originally published in The Gold Sheet
At a recent workshop on inspection trends at the recent PDA/FDA joint regulatory conference held in Washington on Sept. 24 FDA official Edwin Rivera noted that in terms of a firm's investigation of out-of-specification (OOS) test results, "the concern is that once you are in the Phase 2 investigation of the OOS failure the emphasis should be on the investigation and trying to determine the root cause. Often times what we see during our inspection is that the companies are pretty quick to do a re-test and a re-sample. We at FDA say in the OOS guidance that once you are in the Phase 2 a true OOS investigation should place more focus on the investigation and trying to find a root cause.
You may also be interested in...
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.